Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT01586182
Other study ID # 11-037
Secondary ID
Status Withdrawn
Phase Phase 1/Phase 2
First received April 24, 2012
Last updated September 2, 2015
Start date November 2011
Est. completion date September 2015

Study information

Verified date September 2015
Source Dana-Farber Cancer Institute
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This research study is a Phase I clinical trial. Phase I clinical trials test the safety of an investigational intervention (in this case, the stereotactic radiation boost). Phase I studies also try to define the appropriate dose of the investigational intervention to use for further studies. "Investigational" means that the stereotactic radiation treatment is still being studied and that research doctors are trying to find out more about it. It also means that the FDA has not approved a stereotactic radiation boost for your type of cancer.

In this research study, the investigators are looking for the highest dose of the stereotactic radiation boost that can be given safely. Because the stereotactic radiation boost is so precise, the investigators are testing whether it can be used to increase the dose to the primary tumor without significantly increasing the side effects you experience; the goal is to improve the likelihood of successfully treating the tumor.


Description:

After confirming that you are eligible for this study and your willingness to participate in it, we will perform a radiation treatment stimulation, or "mapping session," within the next two weeks. You may or may not receive intravenous contrast during the process, which allows your physician to better see the blood vessels in your neck. You will be placed in a mask during this process to help keep you in the same place during each treatment. All of this is part of standard radiation treatment.

Approximately 14 days later, you will start radiation treatment to your primary tumor site and to your lymph nodes and chemotherapy in the same week. The chemotherapy will continue to be given one time per week during each week of treatment. You will receive radiation treatment 5 days a week for seven weeks. One day each during the first and second weeks of treatment, instead of the typical radiation dose, you will receive a dose of the stereotactic radiation boost to the site of the primary tumor (total of 2 doses of stereotactic radiotherapy).

Because we are looking for the highest dose of the stereotactic radiation boost that can be administered safely without severe or unmanageable side effects, not everyone who participates in this research study will receive the same dose of the stereotactic radiation boost. The dose you get will depend on the number of participants who have been enrolled in the study before you and how well they have tolerated their doses. We are testing 3 different dose levels for the stereotactic radiation boost; your dose will be one of those 3 doses.

The chemotherapy will be given one time per week, each week, for the duration of the radiation treatment (7 weeks). The chemotherapy is delivered through intravenous fluids that run through a vein in your arm. This is the same chemotherapy that you would receive if you were not participating in the study.

You will be seen by your radiation oncologist at least once every week during treatment.

After the final dose of radiation treatment all subsequent follow-up visits and tests are performed in accordance with standard cancer care. You will see your radiation oncologist, with or without the medical oncologist, at the following time intervals: 1 week after treatment ends, 1 month after treatment ends, 2 months after treatment ends, and then every 3 months for two years. You will undergo a PET-CT scan and neck CT scan at the time of the 3 month appointment.

You will be on the study treatment for about 7 weeks and your progress will be followed as part of the study for 2 years after treatment ends.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date September 2015
Est. primary completion date April 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Previously untreated histologically or cytologically confirmed T2-4, N0-3 HPV16-negative oropharyngeal squamous cell carcinoma or HPV16 positivity with at least a 10 pack-year smoking habit

- Measurable disease

- Life expectancy of greater than 6 months

Exclusion Criteria:

- Other active malignancy within the past 5 years (except for non-melanoma skin cancer or carcinoma in situ of the cervix)

- Primary tumor size > 6 cm

- Prior history of head and neck radiotherapy

- Receiving any other study agents

- History of allergic reactions attributed to compounds of similar chemical or biologic composition to cisplatin

- Uncontrolled intercurrent illness

- Pregnant or breastfeeding

- HIV positive on combination antiretroviral therapy

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Radiation:
Stereotactic Body Radiotherapy
Starting dose is 5.5 Gy x 2 boosts in addition to 57.24 Gy to the primary disease

Locations

Country Name City State
United States Brigham and Women's Hospital Boston Massachusetts
United States Dana-Farber Cancer Institute Boston Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Dana-Farber Cancer Institute

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Determination of MTD Determination of the MTD and dose-limiting toxicities of a stereotactic boost to chemoradiotherapy for poor-prognosis oropharyngeal squamous cell carcinoma 2 years Yes
Primary Two Year Local Control Rate Local failure is defined as biopsy-proven recurrent disease 2 years No
Secondary Safety and Tolerability of Stereotactic Boost To evaluate the safety and tolerability of a stereotactic boost to chemoradiotherapy, including both acute and long-term toxicity 2 years Yes
Secondary Overall Survival To determine the 2 year overall survivial 2 years No
Secondary Disease-Free Survival To determine the 2-year disease-free survival 2 years No
See also
  Status Clinical Trial Phase
Recruiting NCT05540899 - Testing the Safety of Giving a Standard Dose of Radiation Over a Shorter Period of Time for Patients Who Had Surgery for Intermediate-Risk Head and Neck Cancer Phase 1
Active, not recruiting NCT03669718 - A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC Phase 2
Recruiting NCT04151134 - Evaluation of Tongue Base MucOsectomy & Step sErial Sectioning
Not yet recruiting NCT06380686 - Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome
Recruiting NCT05119036 - Adjuvant Treatment Deintensification After Transoral Surgery for Human Papillomavirus-Positive Squamous Cell Carcinoma Phase 2
Recruiting NCT04031534 - Study of Hypoxia Measured in F-Miso PET/Scan and MRI in Patients With Squamous Cells Carcinoma Phase 2
Not yet recruiting NCT05608369 - Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC Phase 2
Terminated NCT02552550 - Swallowing, Speech and Quality of Life of Patients With Carcinoma of the Oropharynx
Active, not recruiting NCT04398524 - A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC Phase 2
Recruiting NCT06030440 - De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck Phase 2/Phase 3
Completed NCT01663259 - Reduced-intensity Therapy for Oropharyngeal Cancer in Non-smoking HPV-16 Positive Patients N/A
Recruiting NCT04104945 - p16+ Oropharyngeal Cancer Radiation Optimization Trial Reducing Elective Treatment Volumes (PROTEcT) N/A
Not yet recruiting NCT05962242 - HPV DNA-Guided Radiotherapy De-intensification of Head and Neck Squamous Cell Carcinoma Phase 2
Not yet recruiting NCT06061705 - Identification of Individual Histological and Blood Markers in Patients With Recurrent or Metastatic Upper Aerodigestive Tract Squamous Cell Carcinoma in Response to Immunotherapies N/A
Active, not recruiting NCT03370276 - Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma Phase 1/Phase 2
Recruiting NCT06112535 - Prospective Clinical Study to Assess the Safety and Efficacy of Versius, in Transoral Robotic Surgery N/A
Completed NCT01921426 - A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck Phase 1
Completed NCT01181648 - Long-Term Impact of Human Papillomavirus (HPV) on Quality of Life
Recruiting NCT05918510 - Observational Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx and Occult Tumors Positive for Papilloma Virus
Recruiting NCT05894083 - A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze) Phase 2